Psylo is developing next-generation psychedelics using computational chemistry to optimize the pharmacology of compounds inspired by psychedelics that exist in nature. Psylo's objective is to develop widely accessible mental health medications that offer an improved treatment alternative to current SSRIs, using natural psychedelic molecules as the starting point.

Psylo

Biotech startup Psylo closes US$8m seed round on psychedelic treatment - Capital Brief

The RockShox Psylo is like a cut-price Lyrik for £580, but it’s inside where things get really clever - MBR

Psylo Newsletter - August 2022

 Psylo Raises $8M in Seed Funding 

Pα+ Psychedelic Bulletin #166: Crenshaw and Musk Weigh In on MDMA; Drug Devs Clarify Trial Design In Wake of AdComm; Mini Interview: Joshua Ismin, Psylo - Psychedelic Alpha

The RockShox Psylo Fork is a More Affordable Lyrik Alternative - Singletracks.com

Psychedelic biotech startup Psylo raises $1.1m to treat mental health issues with the key ingredient in magic mushrooms - Startup Daily

Psylo Celebrates Historic FDA Submission of MDMA-Assisted Therapy for PTSD by MAPS PBC

Interview | Josh Ismin, Psylo - Psychedelic Alpha


              Neuroscience Newsletter - 2024 September — PSYLO
            

Psychedelic Biotech Strikes Big Pharma Agreement 

Psychedelic drugs development landscape witnessing remarkable surge: GlobalData - ETHealthWorld

Psylo Newsletter - October 2022

Psylo partnership to deliver psychedelic treatments for mental health


              Structural neural plasticity evoked by rapid-acting antidepressant interventions - Nature Reviews Neuroscience
            

Psylo announces sponsored research agreement with Daiichi Sankyo to develop non-hallucinogenic psychiatric therapies

How Psylo and Enosis Therapeutics are using tech to tackle medicinal psychedelics - SmartCompany

Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore

Psylo's US trip: why the psychedelics startup is keeping one foot in Australia as it expands stateside

Psylo Newsletter - June 2022

Superseeder: psychedelic biotech Psylo plants $12 million in latest ‘Seed’ round - Startup Daily

Biotech startup Psylo partners with University of Sydney to deliver psychedelic treatments for mental health in Australia - BSA bureau

Marzocchi’s new Z1 and Z2 forks promise improved Fox-like performance at a lower price - MBR

$6 million boost for industry research projects

I am delighted to be speaking at the 7th Neuropsychiatric Drug Development Summit in Boston next week! I will speak on the panel, "Navigating the Commercial Challenges of Reimbursement & Market Access to Streamline Route to Market for Psychiatric Therapeutics."

I’ll be speaking alongside Dina Burkitbayeva (Freedom Biosciences), Charmaine Lykins (MapLight Therapeutics, Inc.) and Elemer Piros (Rodman & Renshaw), where we’ll address crucial questions such as:
- How can we effectively commercialize neuropsychiatric products and secure payer support?
- What strategies can help lower human resource costs to boost profitability?
- How do we identify the most valuable areas for commercial investment in psychiatry?

I'm looking forward to engaging with industry leaders and contributing to the future of psychiatric therapeutics.

🗓 September 26th at 4:00 PM
🤝 If you're attending, let’s connect!

Registration link here: https://ter.li/0c7c90 
World CNS Series Ellie Rapps The George Institute for Global Health Psylo

Superseeder: psychedelic biotech Psylo plants $12 million in latest ‘Seed’ round

Did you know that #neurological disorders are now the leading cause of disability worldwide? While #MentalHealth conditions contribute nearly 5% to the global disease burden.

Our October newsletter explores the disease burden and highlights the large #TreatmentGap for these conditions, especially in low-income countries where up to 96% of affected individuals go untreated. Could neuroplasticity-promoting therapies, like #neuroplastogens, offer new hope for treating depression and neurodegenerative diseases?

🧠 Our newsletter also features research highlights, including:
 - Antidepressant discontinuation and psilocybin efficacy
- Psilocybin-assisted neurofeedback treatment
- Study design and its impact on psychedelic efficacy outcomes
- Psychedelics in autistic adults
- BDNF as a predictor of antidepressant response
- The role of serotonin receptors in disease mechanisms

🥼 Plus, new clinical trials exploring psilocybin for ALS and cognitive control in seizure disorders, and the use of THC as an active placebo!

👉👉Explore these topics and more in our latest newsletter: https://lnkd.in/gEe-fJ8i
Subscribe today to stay on the cutting edge of neuroscience research and clinical advancements.

PSYLO ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH DAIICHI SANKYO TO DEVELOP NON-HALLUCINOGENIC PSYCHIATRIC THERAPIES

Psylo Newsletter - February 2023

Psylo Newsletter - May 2022


        
        
  

  
      
      

  

  

    

    

    
  

o2h platinum partner

Psylo signs research deal with Daiichi Sankyo for psychiatric therapies

News

New RockShox Psylo fork borrows from top-flight Pike and Lyrik – at half the price - BikeRadar

Psylo and Future Medicine - Humans of Purpose podcast with Dr Dilara Bahceci

< Back to blog

How Psylo and Enosis Therapeutics are using tech to tackle medicinal psychedelics

Timing is key for behavioural benefits of psychedelics

First Ride: The Sub-$600 RockShox Domain and Psylo Forks - Pinkbike.com

Psylo Newsletter - November 2022

Psylo Newsletter - July 2022

Psylo Newsletter - April 2022

Australia’s food, drug and finance regulators can be progressive

Psylo Newsletter - September 2022

Psylo Newsletter - March 2022

o2h Kickstarter: Innovate America

Thank you for celebrating an incredible year with us! We’re immensely grateful to everyone who joined Psylo’s end-of-year celebration last night. Your support and collaboration have made this a truly fantastic year.

A special thanks to our amazing investors, including Tenmile, Main Sequence, UNSW Founders and M8 Ventures, whose belief in our vision continues to drive us forward. 

Here’s to an even bigger and brighter 2025! 🌟

(More amazing and professional photos from the evening to come!)

 Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC Deep Tech Competition in Singapore 

We’re excited to share that Psylo, Tessara Therapeutics, and the Brain and Mind Centre, University of Sydney have been awarded a $3 million CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders! 

Together, we're accelerating the development of neuroplastogens, with a focus on methamphetamine addiction. 

This collaboration will leverage Psylo’s pioneering neuroplastogens, Tessara’s novel microtissue technology and the University of Sydney’s neuroscience expertise to address addiction and mental health challenges.

We’re grateful for the support of the Australian Government and excited to join forces to develop innovative, brain-rewiring therapies that offer new hope for those struggling with addiction. 

👉 Read more about this exciting project here: https://lnkd.in/gGjWkE_s

🧪 Joshua Ismin 💊 Sam Banister Nick Everett ⚗️ William Jorgensen Jin Tan Joanna Hare Lachlan Whish  Mario de la Fuente, PharmD, PhD Dilara Bahceci Krista Licata Christos Papadimitriou Paul Adlard Alan Kozikowski Alex Kwan Graham Pechenik Dr. Jianmin Duan Anna Goldys Ryan Bethencourt Ian Torrance Eric J. Nestler, MD, PhD John Krystal Donald Gehlert, Ph.D. Forest Heims Main Sequence Tenmile Lionheart Ventures Focalpoint Partners Negev Capital Possible Ventures Startmate UNSW Founders Radar Ventures

RockShox's new budget Psylo fork, Kali's carbon full-face lid, Fox's Boa-equipped flat-pedal shoes and G-Form's chunky Spike torso protector - BikeRadar

Psylo Newsletter - March 2023

Partnership with biotech start-up Psylo will help deliver psychedelic treatments for mental health - University of Sydney

All-New 2025 RockShox Psylo & Domain Forks Channel Pike & Zeb MTB Inspiration for - BikeRumor.com

RockShox Revelation retires – replaced by Psylo - off.road.cc

Biotechs scramble as Australia leads world in psychedelics - The Australian Financial Review

back to news

Psychedelic biotech startup Psylo raises $5 million Seed round - Startup Daily

Psylo Announces First Close on $8 Million Series Seed Financing to Advance Next-Generation Neuroplastogens

Want a RockShox Lyrik but are put off by the high price? The new Psylo trail MTB fork gives similar performance but only costs half as much - Bike Perfect

 Psychedelic drug industry collaborations increased by 500% since 2019 

Psylo signs research deal with Daiichi Sankyo for psychiatric therapies - Pharmaceutical Technology

Check out how Psylo (Startmate,  W21) and Enosis Therapeutics are using tech to tackle medicinal psychedelics 🦠 

"Psylo has taken a different approach to psychedelic therapy by developing synthetic compounds inspired by psychedelics.

Unlike psilocybin or MDMA, these compounds are designed to remove the hallucinogenic properties, offering patients the therapeutic benefits without the need for intense, supervised psychedelic experiences.

🧪 Joshua Ismin, co-founder and CEO of Psylo, explained the company is focused on creating novel compounds — known as neuroplastogens — which work on the same receptors as traditional psychedelics, but don’t induce hallucinations."

Read more here!!

https://lnkd.in/gz-DkJQE

Psylo de François Robic (2020) - Unifrance Films

The big name VCs backing Aussie magic mushrooms start-up - The Australian Financial Review

ROCKSHOX UNVEILS PSYLO FORK! - Mountain Bike Action

ROCKSHOX INTRODUCES NEW DOMAIN AND PSYLO FORKS - Mountain Bike Action

 Biotechnology Start-Up Psylo Wins Hello Tomorrow APAC ... 

Next-generation psychedelics: should new agents skip the trip?

💜 WE VISITED Psylo💜 

....and they have some very exciting news! 👀

Last week, co-founder of Psylo, 🧪 Joshua Ismin welcomed the team and community into the Psylo labs at UNSW!

🎉 🎊 More importantly... Psylo made an announcement at the end of last week: 

"We’re excited to share that Psylo, Tessara Therapeutics, and the Brain and Mind Centre, University of Sydney have been awarded a $3 million CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders!"

Check out the full post here 👉🤠 https://loom.ly/qF5_5gI

RockShox Psylo Gold RC fork review - BikeRadar

Psylo Newsletter - April 2023

The Psylo team had a fantastic day connecting with Scott Thompson and his team at the University of Colorado Anschutz Medical Campus to learn about the important research they’re leading on depression mechanisms and the action of antidepressants and psychedelics, right here in Colorado.

We're thrilled to be part of this incredible ecosystem and look forward to contributing to the incredible research happening in our state!

Devin Effinger, PhD, Joselyn Calderon, Jillian King, 💊 Sam Banister, Krista Licata, Dilara Bahceci, University of Colorado Boulder

MDMA and Psilocybin are now legal in Australia

Lifting depression: Are hallucinations compulsory?

Australian startup Psylo advances depression treatment with Japanese pharma firm Daiichi Sankyo


              How Psylo and Enosis Therapeutics are using tech to tackle medicinal psychedelics
            

Psylo

Business:

Drug notes:

About: